Hematopoietic stem cell gene therapy for the treatment of SYNGAP1‐related non‐specific intellectual disability

Abstract

BackgroundSynaptic Ras GTPase activating protein 1 (SYNGAP1)‐related non‐specific intellectual disability is a neurodevelopmental disorder caused by an insufficient level of SynGAP1 resulting in a dysfunction of neuronal synapses and presenting with a wide array of clinical phenotypes. Hematopoietic stem cell gene therapy has the potential to deliver therapeutic levels of functional SynGAP1 to affected neurons upon transduction of hematopoietic stem and progenitor cells with a lentiviral vector.MethodsAs a novel approach toward the treatment of SYNGAP1, we have generated a lentiviral vector expressing a modified form of SynGAP1 for transduction of human CD34+ hematopoietic stem and progenitor cells. The gene‐modified cells were then transplanted into adult immunodeficient SYNGAP1+/− heterozygous mice and evaluated for improvement of SYNGAP1‐related clinical phenotypes. Expression of SynGAP1 was also evaluated in the brain tissue of transplanted mice.ResultsIn our proof‐of‐concept study, we have demonstrated significant improvement of SYNGAP1‐related phenotypes including an improvement in motor abilities observed in mice transplanted with the vector transduced cells because they displayed decreased hyperactivity in an open field assay and an increased latency to fall in a rotarod assay. An increased level of SynGAP1 was also detected in the brains of these mice.ConclusionsThese early‐stage results highlight the potential of this stem cell gene therapy approach as a treatment strategy for SYNGAP1.